Senzime
- Company typePublic
- Founded1999
- HeadquartersUppsala, Sweden
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Senzime firmographics
Firmographics- Name
- Senzime
- Legal name
- Senzime AB (publ)
- Website
- https://www.senzime.com/
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Senzime industry classification
Industry- Product category
- Patient Monitoring Systems - Neuromuscular Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts) (HLAHADAJ)
- akta.pro secondary industries
- Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)
Keywords
Where Senzime is headquartered
LocationHeadquarters
- HQ city
- Uppsala
- HQ country
- Sweden
- HQ region
- Europe
Offices3 records
Markets served
Senzime business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- TetraGraph Hardware Systems: Sale of TetraGraph neuromuscular monitoring devices including monitors and sensors. Monitor sales to hospitals and surgical centers, generating recurring sensor revenue.
- EMG Sensors (Recurring): Recurring sales of TetraSens and other EMG sensors for use with TetraGraph systems. Sensors are single-use disposable products requiring regular repurchase.
- TetraAnalytics Software Platform: Cloud-based analytics platform for next-generation TetraGraph users, potentially with subscription or per-user pricing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | No public pricing available |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
Senzime product offering
Product offeringCore offering
Senzime develops, manufactures, and sells precision-based patient monitoring systems for hospitals and surgical centers, centered on the TetraGraph quantitative Train-of-Four (TOF) neuromuscular monitoring platform that uses electromyography (EMG) to optimize dosing of muscle relaxants and assess patient readiness for extubation. The company also sells single-use EMG sensors, a cloud-based analytics platform (TetraAnalytics), an EHR connectivity platform (TetraCom), the EMGINE software suite, and the ExSpiron non-invasive respiratory volume monitoring system acquired from Respiratory Motion.
Product overview
Senzime offers a portfolio of precision-based patient monitoring solutions centered around the TetraGraph system for neuromuscular blockade monitoring during surgery. The product line includes the core TetraGraph neuromuscular monitoring system (available in next-generation and classic versions), TetraSens EMG sensors, TetraCom EHR connectivity platform, TetraAnalytics cloud-based data analytics platform, and EMGINE Software Suite. The ExSpiron non-invasive respiratory volume monitoring system was acquired through Respiratory Motion. Products are designed for use in operating rooms, ICUs, and hospital settings, with a focus on anesthesia-to-recovery patient safety. Senzime operates direct sales teams in the US and Germany, with licensing partners in Japan and China, and distributors covering over 30 markets.
Differentiator
Problem solved
Functional benefit
Brands
- TetraGraph: Quantitative neuromuscular monitoring system using EMG technology for train-of-four monitoring during surgery
- TetraSens
- EMGINE
- TetraCom
- TetraAnalytics
- ExSpiron
Products and services
- TetraGraph Neuromuscular Monitoring System Quantitative Train-of-Four (TOF) neuromuscular monitoring system used by anesthesiologists during surgery to monitor neuromuscular function, optimize dosing of muscle relaxants, and assess patient readiness for extubation. Available in next-generation and classic versions. Used by over 750 hospitals worldwide.
- TetraSens EMG Sensor Single-use EMG sensor designed for use with the TetraGraph system, featuring 50% less dielectric material than legacy sensors. Manufactured in Europe with environmentally friendly process and regional supply chain. Generates recurring sensor revenue for the company.
- TetraAnalytics Data Analytics Platform Cloud-based data analytics platform for next-generation TetraGraph users that transforms invisible patterns into operational insights, featuring flexible data analysis with customizable dashboards, summaries, comparisons, and reports, the Train-of-Four Quality Indicator (TQi), and centralized remote team collaboration tools.
- ExSpiron Respiratory Volume Monitor Non-invasive respiratory volume monitoring system for monitoring respiratory function during and after surgery. Acquired through the Respiratory Motion acquisition in 2022. Addresses respiratory and vital signs monitoring needs outside the operating room.
- TetraCom EHR Connectivity Platform Hospital connectivity platform combining compact hardware gateway with cloud-based software using HL7 messaging standards to enable universal wireless transmission of neuromuscular monitoring data directly into hospital enterprise systems such as Epic and Oracle Health, eliminating manual charting and enabling automated documentation.
- EMGINE Software Suite Software platform for the TetraGraph system including Sirius features with intubation readiness indicator, personalized monitoring, and high-current stimulation capabilities, built on extensive clinical data.
Quantifiable outcome
- 43% reduction in postoperative pulmonary complications when TOFR >0.90 achieved
- +5 more outcomes
Companies that use Senzime
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Senzime technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature6 records
Senzime partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and strategic.
- VizientcoreLeading US Group Purchasing Organization. Vizient agreement removes structural barriers in US procurement process and creates foundation for broader hospital network adoption.
- Premier Inc.coreLeading US Group Purchasing Organization. Premier agreement enables system-wide contracts with hospital networks through GPO procurement.
- HealthTrust Performance GroupcoreLeading US Group Purchasing Organization. HealthTrust agreement covers combined annual purchasing volumes exceeding USD 200 billion with approximately 95% of US hospitals engaging with GPOs.
- Fukuda DenshicorePartnership for distribution and commercialization of Next-generation TetraGraph system in Japan. Fukuda Denshi received regulatory approval from PMDA and launched HN-100 NMT Monitoring Module integrating Senzime's EMG technology. Fukuda Denshi has been active in Japan since 2019.
- Healthcare 21 GroupcoreUK partner facilitating Senzime's NHS hospital contracts. Healthcare 21 enabled the 70-unit order from leading NHS hospital trust, the largest European order for Senzime.
- Fukuda Denshi (US Integration)strategicFukuda Denshi launched HN-100 Neuromuscular Transmission Monitoring Module in US market integrating advanced EMG technology from Senzime AB for real-time neuromuscular function monitoring during anesthesia care.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
Senzime competitors and assessment
Company assessmentDirect peers
- Blink Device Company: Direct competitor in EMG-based quantitative Train-of-Four neuromuscular monitoring with the TOF-Cuff and TOF-Scan products, targeting the same anesthesia provider customers in US and European hospitals. Closest like-for-like peer for TetraGraph.
- Stimdia Medical: Earlier-stage developer of EMG-based neuromuscular monitoring technology competing directly with Senzime's TetraGraph in the perioperative quantitative TOF segment. Closely comparable on technology approach and target use case.
Broad incumbents
- Drägerwerk: Major anesthesia workstation and patient monitoring incumbent whose Infinity and Perseus platforms integrate quantitative neuromuscular monitoring. Competes for the same hospital capital budget and OR footprint but as part of a much broader portfolio.
- GE HealthCare: Broad patient monitoring and anesthesia delivery incumbent with CARESCAPE and Aisys platforms that integrate neuromuscular monitoring modules. Competes for hospital OR monitoring budgets across vital signs and anesthesia.
- Philips (Patient Monitoring): Global patient monitoring leader whose IntelliVue and bedside monitoring ecosystems overlap with Senzime's perioperative monitoring use case, especially in integrated hospital enterprise deployments.
- Masimo: Patient monitoring and pulse oximetry leader whose SedLine brain monitoring and rainbow sensors compete in the perioperative monitoring space; SET pulse oximetry is a standard of care adjacent to neuromuscular monitoring.
- Mindray: Major Chinese patient monitoring and anesthesia equipment manufacturer with broad OR and ICU monitoring portfolios that include neuromuscular modules. Competes on price and on bundled anesthesia solutions globally.
- Edwards Lifesciences: Hemodynamic and minimally invasive patient monitoring incumbent with strong hospital critical-care footprint, including advanced parameters in the OR setting; comparable on enterprise hospital monitoring sales motion but differentiated clinically.
Regional players
- Nihon Kohden: Japanese patient monitoring leader whose OR and bedside monitors overlap with Senzime's perioperative use case; particularly relevant given Senzime's Japan expansion via Fukuda Denshi.
- Fukuda Denshi: Senzime's Japanese licensing partner which launched the HN-100 NMT module integrating Senzime's EMG technology. Comparable as a Japanese anesthesia/monitoring vendor and as a direct commercialization channel for TetraGraph in Japan.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Senzime social profiles
Digital presenceSenzime compliance and trust
Trust signalCompliance3 records
Senzime financial estimates
Financial estimateRevenue estimate
Valuation estimate
Senzime leadership team
Management profileNumber of profiles
Profiles13 records
Senzime subsidiaries and ownership
Company hierarchySubsidiaries1 record
Senzime funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Senzime M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Senzime
What does Senzime do?
Senzime develops, manufactures, and sells precision-based patient monitoring systems for hospitals and surgical centers, centered on the TetraGraph quantitative Train-of-Four (TOF) neuromuscular monitoring platform that uses electromyography (EMG) to optimize dosing of muscle relaxants and assess patient readiness for extubation. The company also sells single-use EMG sensors, a cloud-based analytics platform (TetraAnalytics), an EHR connectivity platform (TetraCom), the EMGINE software suite, and the ExSpiron non-invasive respiratory volume monitoring system acquired from Respiratory Motion.
Is Senzime a public or private company?
Senzime is a public company. It is classified as public and is currently operating.
When was Senzime founded?
Senzime was founded in 1999. It employs 51 to 100 people.
Where is Senzime based?
Senzime is headquartered in Uppsala, Sweden, in the Europe region.
How does Senzime make money?
Three revenue lines are on record. TetraGraph Hardware Systems are the primary driver. The others are EMG Sensors (Recurring) and tetraAnalytics Software Platform.
Who are Senzime's main competitors?
Direct peers on record are Blink Device Company and Stimdia Medical. Broad incumbents are Drägerwerk, GE HealthCare, Philips (Patient Monitoring), Masimo, Mindray and Edwards Lifesciences. Regional players are Nihon Kohden and Fukuda Denshi.
Does Senzime have an API?
No public API is recorded for Senzime.
What industry is Senzime in?
Senzime's product category is Patient Monitoring Systems - Neuromuscular Monitoring. Its primary akta.pro industry code is HLAHADAJ, Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts), with a secondary code of HLACAFAG, Medical-Grade Device Connectivity & Device Management (MDM). Its NAICS code is 334510 and its SIC code is 3845.